(Press-News.org) HOUSTON and SOMERVILLE, Mass. ― The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.
Under the co-development and commercialization agreement, MD Anderson and Generate:Biomedicines will each contribute toward creating optimized, potentially best-in-class therapeutics that can rapidly advance into proof-of-concept clinical trials. The agreement combines Generate:Biomedicines’ integrated machine-learning capabilities and experimental/wet lab capabilities – which are powered by The Generate Platform – with MD Anderson’s clinical research expertise and the translational research and drug development capabilities of the Translational Research to AdvanCe Therapeutics and Innovation in Oncology (TRACTION) platform.
“Together with Generate:Biomedicines, we aim to leverage rapid advancements in generative AI to develop new medicines that are purpose-built for those who do not benefit from existing treatments or who have drug-resistant cancers requiring new options,” said Timothy Heffernan, Ph.D., vice president of Oncology Research for TRACTION at MD Anderson. "By joining The Generate Platform with our integrated translational research and drug development approach, we hope to successfully scale drug discovery and development in a way that has eluded traditional trial-and-error methods.”
By tapping into the programmability and scalability of The Generate Platform, researchers within TRACTION and across the MD Anderson research enterprise will accelerate the pace of drug development and inform clinical translation. TRACTION is a core component of MD Anderson’s Therapeutics Discovery division that deploys a fully integrated translational biology engine to overcome traditional challenges in oncology drug discovery.
“Our collaboration with MD Anderson is an embodiment of innovative and cooperative research purposed to maximize the clinical impact of new therapeutics in oncology,” said Generate:Biomedicines’ Chief Medical Officer, Alex Snyder, M.D. “Together, we aim to deploy disruptive technology that will enable us to completely reimagine how we identify and pursue therapeutic targets, with the goal of creating new therapies for patients faster than ever before.”
Under the agreement terms, Generate:Biomedicines and MD Anderson will share research and development expenses as well as funds generated through commercialization of products that emerge from the collaboration. The organizations also anticipate that MD Anderson will serve as a site and recommend lead investigators for Phase I and II clinical trials of any jointly developed therapeutic product candidates.
-30-
Disclosure
MD Anderson has an institutional conflict of interest with Generate related to this research, and this relationship will be managed according to an MD Anderson Institutional Conflict of Interest Management and Monitoring Plan.
About Generate:Biomedicines
Generate:Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform – which is a continuous loop to generate, build, measure, and learn – can drastically increase the speed at which targets and therapeutics are identified and validated. This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates. Generate:Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate:Biomedicines by visiting GenerateBiomedicines.com or following the company on Twitter and LinkedIn.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
END
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways traditional techniques cannot
2023-04-27
ELSE PRESS RELEASES FROM THIS DATE:
Sounds from nature: A soothing remedy for gambling addiction
2023-04-27
Gambling addiction, also called “pathological gambling” and “gambling disorder (GD),” is known to have severe economic, social, mental, and physical consequences on those affected. One of the major factors contributing to the development and relapse of this disorder is stress. However, studies show that replacing gambling with alternative leisure activities may reduce the likelihood of developing the disorder. In recent years, forest bathing, or “shinrin-yoku,” a form of nature therapy, has emerged ...
Estimating the impact of new high seas activities on the environment: The effects of ocean-surface macroplastic removal on sea surface ecosystems
2023-04-27
“The surface is the skin through which our ocean breathes. It is a critical nursery ground for hundreds, possibly thousands, of species, and it is also one of the most vulnerable regions to human impacts. This is why we must treat the surface with exceptional care. It is an extremely unique and fragile environment, and small impacts at the surface could ripple into large impacts above and below the waves.” - Dr. Rebecca Helm, Assistant Professor of Environmental Science at Georgetown University
New research ...
AI in the ICU
2023-04-27
Clinicians in an intensive care unit need to make complex decisions quickly and precisely, monitoring critically ill or unstable patients around the clock.
Researchers from Carnegie Mellon University's Human-Computer Interaction Institute (HCII) collaborated with physicians and researchers from the University of Pittsburgh and UPMC to determine if artificial intelligence could help in this decision-making process and if clinicians would even trust such assistance.
The team gave 24 ICU physicians access to an AI-based ...
Record ammonia production achieved with inexpensive cobalt catalyst at low temperatures
2023-04-27
Ammonia (NH3) is one of the most widely produced chemicals in the world, with a production of over 187 million tons in 2020. About 85% of it is used to produce nitrogenous fertilizers, while the rest is used for refining petroleum, manufacturing a wide range of other chemicals, and creating synthetic fibers such as nylon. However, all this comes at a high energy cost. Currently, most of the ammonia is produced using the conventional Haber-Bosch process, which requires combining nitrogen and hydrogen at high temperatures (400-450°C) and pressures (200 atmospheres). As a result, scientists ...
Analyzing CAR-T cells with image cytometry for potential solid tumor treatments
2023-04-27
Oak Brook, IL – The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.
Featured in this month’s issue is the article “High-Throughput Method to Analyze the Cytotoxicity of CAR-T Cells in a 3D Tumor Spheroid Model Using Image Cytometry,” by Zurowski, et al, where the authors focus on the use of chimeric ...
10 popular diets scored for heart-healthy elements; some need improvement
2023-04-27
Statement Highlights:
A new American Heart Association scientific statement assesses and scores the heart healthiness of popular dietary patterns.
Several dietary patterns, including the DASH-style eating plan, Mediterranean, pescatarian and vegetarian eating patterns, received top ratings for aligning with the Association’s dietary guidance.
A few eating patterns, including Paleo and ketogenic diets, contradict the Association’s guidance and did not rank as heart-healthy eating patterns.
The statement suggests opportunities for dietary research and interventions to promote health equity, recognizing the importance of social determinants of health in shaping dietary ...
Twilight zone at risk from climate change
2023-04-27
Life in the ocean’s “twilight zone” could decline dramatically due to climate change, new research suggests.
The twilight zone (200m to 1,000m deep) gets very little light but is home to a wide variety of organisms and billions of tonnes of organic matter.
The new study warns that climate change could cause a 20-40% reduction in twilight zone life by the end of the century.
And in a high-emissions future, life in the twilight zone could be severely depleted within 150 years, with no recovery for ...
Researchers from ISGlobal and LSHTM call for incorporating heat stress indices into communication of dangerous heat waves
2023-04-27
In the summer of 2022, over 20,000 excess deaths across Spain, France, Germany and Great Britain were suggested to have been linked to extremely hot weather. In the context of global warming where climate models point to the fact that extreme heat waves are likely to increase both in frequency and magnitude, preventive measures and adequate communication of dangerous conditions take on special relevance. In a Brief Communication published in npj Climate and Atmospheric Science, researchers from the Barcelona Institute for Global Health (ISGlobal), a centre supported ...
Discovery could improve survival of bladder cancer patients
2023-04-27
· Bladder cancer is the fourth-most diagnosed cancer in men, and survival for patients with advanced bladder is less than a year
· Doctors don’t know which bladder cancer patients will benefit from immunotherapy
·Treatment of patients with ineffective therapy causes unneeded harm and delays treatment with optimal therapies
Chicago --- In a discovery that could improve the survival of bladder cancer patients, Northwestern Medicine scientists have developed a biomarker signature test to predict which ...
Odyssey of a 90-Year-Old from Israel, the United Kingdom, Australia and Singapore
2023-04-27
Down Memory Lane: Peter Ellinger’s Memoirs details the life of Law Professor Peter Ellinger, which has taken him around the world from Israel, to the United Kingdom, Australasia and finally Singapore, where he has chosen to retire. From his escape from Austria during Hitler’s reign, to his growing-up years in Israel, academia and legal practice, and his eventual retirement, this book takes you on a journey in time alongside Professor Ellinger.
Professor Ellinger is a Professor Emeritus of the National University of Singapore ...
LAST 30 PRESS RELEASES:
Bacteria breakthrough could accelerate mosquito control schemes
Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University
Medicaid funding for addiction treatment hasn’t curbed overdose deaths
UVA co-leads $2.9 million NIH investigation into where systems may fail people with disabilities
With the help of AI, UC Berkeley researchers confirm Hollywood is getting more diverse
Weight loss interventions associated with improvements in several symptoms of PCOS
Federal government may be overpaying for veterans’ health care in Medicare Advantage plans
Researchers awarded $2.5 million grant to increase lung cancer screenings in underserved communities
New trigger proposed for record-smashing 2022 Tonga eruption
Lupus Research Alliance announces Lupus Research Highlights at ACR Convergence 2024
Satellite imagery may help protect coastal forests from climate change
The secrets of baseball's magic mud
Toddlers understand concept of possibility
Small reductions to meat production in wealthier countries may help fight climate change, new analysis concludes
Scientists determine why some patients don’t respond well to wet macular degeneration treatment, show how new experimental drug can bridge gap
Did the world's best-preserved dinosaurs really die in 'Pompeii-type' events?
Not the usual suspects: Novel genetic basis of pest resistance to biotech crops
Jill Tarter to receive Inaugural Tarter Award for Innovation in the search for life beyond earth
Survey finds continued declines in HIV clinician workforce
Researchers home in on tumor vulnerabilities to improve odds of treating glioblastoma
Awareness of lung cancer screening remains low
Hospital COVID-19 burden and adverse event rates
NSF NOIRLab astronomers discover the fastest-feeding black hole in the early universe
Translational science reviews—a new JAMA review
How the keto diet could one day treat autoimmune disorders
Influence of tool corner radius on chip geometrical characteristics of machining Zr-based bulk metallic glass
Megan Huisingh-Scheetz, MD, MPH, of the University of Chicago recognized with AFAR’s Terrie Fox Wetle Rising Star Award in Health Services and Aging Research
Steven N. Austad, PhD, to receive inaugural George M. Martin Lifetime Achievement in Mentoring Award
Jeremy D. Walston, MD, of Johns Hopkins University to receive AFAR 2024 Irving S. Wright Award of Distinction
SwRI receives $23 million in U.S. Air Force contracts to sustain aging aircraft
[Press-News.org] MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AIMulti-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways traditional techniques cannot